SEARCH

SEARCH BY CITATION

References

  • 1
    Troisi CL, Hollinger FB, Hoots WK, Contant C, Gill J, Ragni M, Parmley R, et al. A multicenter study of viral hepatitis in a United States hemophilia population. Blood 1993; 81:14121418.
  • 2
    Tedder RS, Briggs M, Ring C, Tuke PW, Jones P, Savidge GF, Rodgers B, et al. Hepatitis C antibody profile and viremia prevalence in adults with severe haemophilia. Br J Haematol 1991; 79:512515.MEDLINE
  • 3
    Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs. Effect of coinfection with human immunodeficiency virus. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6:602610.
  • 4
    Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of hemophilic patients. Br J Haematol 1994; 87:555561.MEDLINE
  • 5
    Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94:746752.MEDLINE
  • 6
    Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, et al. Immunosupression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91:25632568.MEDLINE
  • 7
    Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, et al. Mortality from liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350:14251431.MEDLINE
  • 8
    Lessens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 79:12541258.
  • 9
    Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues of coinfection. Am J Med 1999; 107:79S84SMEDLINE
  • 10
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults with HIV and role of hepatitis B or C infection. JAMA 2000; 283:7480.MEDLINE
  • 11
    Puoti M, Gargiulo F, Roldan EQ, Chiodera A, Palvarini L, Spinetti A, Zaltron S, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during early phases of combination antiretroviral treatment. J Infect Dis 2000; 181:20332036.MEDLINE
  • 12
    John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HCV infected patients with HIV protease inhibitors: An immune restoration disease? AIDS 1998; 12:22892293.MEDLINE
  • 13
    Zybelberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27:12551258MEDLINE
  • 14
    Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, Martinez-Odriozola P, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585591.MEDLINE
  • 15
    Causse X, Payen JL, Izopet J, Babany G, Girardin MF. Does HIV infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter propective study. J Hepatol 2000; 32:10031010.MEDLINE
  • 16
    Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:13761379.MEDLINE
  • 17
    Sim SM, Hoggard PG, Sales SD, Phiboonbanakit D, Hart CA, Back DJ. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. AIDS Res Hum Retrovirol 1998; 14:16611667.
  • 18
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:14851492.MEDLINE
  • 19
    Davis GL, Esteban R, Rustgi VK, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:14931499.MEDLINE
  • 20
    Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non A non B hepatitis in patients with HIV infection. Gastroenterology 1989; 97:15591561.MEDLINE
  • 21
    Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:18001805.MEDLINE
  • 22
    Sauleda S, Esteban JI, Altisent C, Puig L, Esteban R, Guardia J. Treatment with Interferon plus Ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000; 83:807810.MEDLINE
  • 23
    Landau A, Batisse D, Van Huyen JP, Piketty C, Bloch F, Pialoux G, Belec L, et al. Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14:839844.MEDLINE
  • 24
    Morsica G, De Bona A, Uberti-Foppa C, Sitia G, Finazzi R, Lazzarin A. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 2000; 14:16561658.MEDLINE
  • 25
    Dieterich DT, Weisz KB, Goldman DJ, Malicdem ML. Combination treatment with interferon (IFN) and ribavirin (RBV) for hepatitis C (HCV) in HIV coinfected patients. 50th AASLD Annual Meeting. Dallas. November 1999 [abstract 266a].
  • 26
    Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694697.MEDLINE
  • 27
    McHutchinson JG, Poynard T, Harvey J, Garaud JJ, Albrecht JK. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin. 51st AASLD Annual Meeting. Dallas. October 2000 [abstract 223a].
  • 28
    Landau A, Batisse D, Piketty C, Jian R, Kazatchkine MD. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14:18571858.MEDLINE